

TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



NAME	Dr. Vinay Cł MD (Pathology a Chairman & Cor		t CEO & Consultant	Pathologist
	: Mr. ASHOK OBEROI			
AGE/ GENDER	: 70 YRS/MALE		PATIENT ID	: 1618008
COLLECTED BY	:		REG. NO./LAB NO.	: 012412100007
REFERRED BY	:		<b>REGISTRATION DATE</b>	: 10/Dec/2024 08:43 AM
BARCODE NO.	:01522242		COLLECTION DATE	: 10/Dec/2024 09:21AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 10/Dec/2024 11:26AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,	AMBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	CT INIT	CAL CHEMIS	TRY/BIOCHEMIST	'DV
	CLINI		) FILE : BASIC	K1
CHOLESTEROL TOT	AI · SERIM	99.14	mg/dL	<b>OPTIMAL:</b> < 200.0
by CHOLESTEROL OXIL		55.14	ing/ uL	BORDERLINE HIGH: 200.0 -
				239.0 HIGH CHOLESTEROL: > OR =
				240.0
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		200.98 <sup>H</sup>	mg/dL	OPTIMAL: < 150.0
by GLYCEROL PHOSPH.	ATE UXIDASE (ENZYMATIC)			BORDERLINE HIGH: 150.0 - 199.0
				HIGH: 200.0 - 499.0
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		00.0×I	mg/dI	VERY HIGH: > OR = 500.0 LOW HDL: < 30.0
		29.25 <sup>L</sup>	mg/dL	BORDERLINE HIGH HDL: 30.0
				60.0 IUCH UDL - OD - 60.0
LDL CHOLESTEROL:	SFRUM	29.69	mg/dL	HIGH HDL: > OR = 60.0 OPTIMAL: < 100.0
by CALCULATED, SPECTROPHOTOMETRY		20.00	ing, all	ABOVE OPTIMAL: 100.0 - 129.0
				BORDERLINE HIGH: 130.0 - 159.0
				HIGH: 160.0 - 189.0
			( )	VERY HIGH: $> OR = 190.0$
NON HDL CHOLESTE by CALCULATED, SPEC		69.89	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0
				BORDERLINE HIGH: 160.0 -
				189.0 HIGH: 190.0 - 219.0
				VERY HIGH: > OR = 220.0
VLDL CHOLESTEROI		40.2	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERU		399.26	mg/dL	350.00 - 700.00
by CALCULATED, SPEC		2 20		
CHOLESTEROL/HDL by CALCULATED, SPEC		3.39	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







Dr. Vinay ChopraDr. Yugam ChopraMD (Pathology & Microbiology)MD (Pathology)Chairman & Consultant PathologistCEO & Consultant Pathologist					
NAME	: Mr. ASHOK OBEROI				
AGE/ GENDER	: 70 YRS/MALE		PATIENT ID	: 1618008	
COLLECTED BY	:		REG. NO./LAB NO.	: 012412100007	
REFERRED BY	:		<b>REGISTRATION DATE</b>	: 10/Dec/2024 08:43 AM	
BARCODE NO.	:01522242		<b>COLLECTION DATE</b>	: 10/Dec/2024 09:21AM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB		<b>REPORTING DATE</b>	: 10/Dec/2024 11:26AM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	AD, AMBALA CANT	Т		
Fest Name		Value	Unit	<b>Biological Reference interval</b>	
LDL/HDL RATIO: SERUM by Calculated, spectrophotometry		1.02	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0	
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY6.1		6.87 <sup>H</sup>	RATIO	3.00 - 5.00	

## **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report \*\*\*





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

